The independent source for health policy research, polling, and news.
1,181-1,200 of 1,312 results
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
An expert geriatrician says the benefits for the patient, such as alleviating pain and maintaining independence, must be weighed against the possible risks. Her motto: ‘start low and go slow.’
Alzheimer's researchers hold onto hope after another promising trial ends in disappointment.
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.
African-American women are more likely to be infected with HIV than other women. So the District of Columbia is launching an effort to inform them about PrEP, medication that can reduce their risk.
The designation, which is made by the Food and Drug Administration, allows drugmakers to claim seven years of market exclusivity.
Orphan drugs for rare diseases have helped or saved hundreds of thousands of patients like 2-year-old Luke Whitbeck, but families and insurers are picking up the astronomical cost.
Drugmakers have brought almost 450 orphan drugs to market and collected rich incentives but nearly a third of those products aren’t new or were repurposed multiple times, an investigation shows.
Follow the twists and turns of the orphan drug industry over the past three decades.
Check out all the drugs the FDA has approved to treat rare diseases. You can search by brand name, or by disease, and see familiar names that were first sold on the mass market or all the drugs that won FDA approval to treat more than one rare disease.
The former Congressman championed the Orphan Drug Act decades ago but now he fears it’s being manipulated to make money.
President Barack Obama recounted his health care accomplishments in his farewell address to the nation Tuesday night.
© 2026 KFF